Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Net Cash Flow (2016 - 2025)

Cardiff Oncology (CRDF) has disclosed Net Cash Flow for 15 consecutive years, with $7.3 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow fell 80.91% to $7.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$34.0 million through Dec 2025, down 214.04% year-over-year, with the annual reading at -$34.0 million for FY2025, 214.04% down from the prior year.
  • Net Cash Flow hit $7.3 million in Q4 2025 for Cardiff Oncology, up from -$649000.0 in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $38.4 million in Q4 2024 to a low of -$116.3 million in Q1 2021.
  • Historically, Net Cash Flow has averaged -$5.7 million across 5 years, with a median of -$1.3 million in 2021.
  • Biggest five-year swings in Net Cash Flow: crashed 12570.92% in 2021 and later surged 498.44% in 2024.
  • Year by year, Net Cash Flow stood at -$1.2 million in 2021, then crashed by 93.94% to -$2.4 million in 2022, then soared by 370.97% to $6.4 million in 2023, then soared by 498.44% to $38.4 million in 2024, then plummeted by 80.91% to $7.3 million in 2025.
  • Business Quant data shows Net Cash Flow for CRDF at $7.3 million in Q4 2025, -$649000.0 in Q3 2025, and -$13.3 million in Q2 2025.